PSA、FPSA检测和骨显像对前列腺癌骨转移的诊断价值  

The Diagnostic Role of PSA、FPSA and Bone Scintigraphy for Skeletal Metastasis of Prostate Cancer

作　　者：谢红军[1] 陈明曦[1] 宋文忠[1] 黄劲[1] 迟殊[1] 

机构地区：[1]四川省人民医院核医学科,四川成都610072

出　　处：《四川肿瘤防治》2005年第3期156-157,共2页Sichuan Journal of Cancer Control

摘　　要：目的:探讨联合应用前列腺特异性抗原(PSA)、游离PSA(FPSA)检测和全身骨显像诊断前列腺癌骨转移的意义。方法:回顾性分析70例经临床确诊的前列腺癌患者,全部行血清PSA、FPSA测定,并作全身骨显像。结果:PSA<4ng/ml在14例病人中,发生骨转移者7例,诊断阳性率为50%;PSA4ng/ml^20ng/ml共7例,发生骨转移者6例,诊断阳性率为87%;PSA>20ng/ml组49例,发生骨转移45例,阳性率为92%。结论:PSA、FPSA检测结合全身骨显像,可尽早、全面地发现前列腺癌患者全身骨转移。Objective： To evaluate the role of prostate specific antigen （PSA）. free prostate specific antigen （FPSA） and bone scintigraphic imaging in diagnosis of skeletal metastasis of prostate cancer. Methods ： 70 patients with prostate cancer were made bone scintigraphy and were detected the concentration of PSA and FPSA. Results： 7 cases of 14 cases（50% ） with PSA 〈4ng/ml had skeletal metastasis;6 of 7 cases （87%） with PSA 4ng/ml -20ng/ml had skeletal metastasis. 45 of 49 cases（ 92% ） with PSA 〉20ng/ml had skeletal metastasis. Conclusion： Detection of PSA and FPSA combined with bone scintigraphy is a valuable scheme for diagnosis of skeletal metstasis of prostate cancer.

关 键 词：前列腺特性异性抗原 游离前列腺特异性抗原 全身骨显像 前列腺癌 骨转移 

分 类 号：R737.25[医药卫生—肿瘤] R730.44[医药卫生—临床医学]